Edition:
United Kingdom

Celsion Corp (CLSN.OQ)

CLSN.OQ on NASDAQ Stock Exchange Capital Market

2.75USD
4:01pm BST
Change (% chg)

$0.10 (+3.77%)
Prev Close
$2.65
Open
$2.63
Day's High
$2.81
Day's Low
$2.63
Volume
37,216
Avg. Vol
25,736
52-wk High
$6.06
52-wk Low
$1.25

Chart for

About

Celsion Corporation is an oncology drug development company. The Company's product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall... (more)

Overall

Beta: 0.88
Market Cap(Mil.): $27.98
Shares Outstanding(Mil.): 8.35
Dividend: --
Yield (%): --

Financials

  CLSN.OQ Industry Sector
P/E (TTM): -- 84.11 32.75
EPS (TTM): -8.37 -- --
ROI: -78.33 1.56 14.38
ROE: -191.72 2.43 16.07

BRIEF-Celsion Phase III Clinical Study Of Thermodox In Combination With Radiofrequency Ablation To Continue According To Protocol

* PHASE III CLINICAL STUDY OF THERMODOX IN COMBINATION WITH RADIOFREQUENCY ABLATION TO CONTINUE ACCORDING TO PROTOCOL Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

09 Apr 2018

BRIEF-Celsion Corporation Provides Corporate Update And 2018 Outlook

* CELSION CORPORATION PROVIDES CORPORATE UPDATE AND 2018 OUTLOOK

18 Jan 2018

BRIEF-Celsion Announces FDA Clearance Of The OVATION II Study For The Evaluation Of GEN-1 Immunotherapy

* CELSION ANNOUNCES FDA CLEARANCE OF THE OVATION II STUDY FOR THE EVALUATION OF GEN-1 IMMUNOTHERAPY TO TREAT NEWLY DIAGNOSED STAGE III/IV OVARIAN CANCER

04 Jan 2018

Earnings vs. Estimates